TaiMed Biologics Inc. (TPEX:4147)

Market Cap	27.01B
Revenue (ttm)	622.61M
Net Income (ttm)	-141.65M
Shares Out	273.08M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,712,348
Average Volume	2,389,001
Open	103.00
Previous Close	99.70
Day's Range	97.50 - 107.00
52-Week Range	66.60 - 116.50
Beta	0.43
RSI	65.16
Earnings Date	Mar 25, 2025

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4147

Financial Performance

In 2023, TaiMed Biologics's revenue was 491.78 million, a decrease of -12.65% compared to the previous year's 563.01 million. Losses were -194.81 million, -27.66% less than in 2022.